Starting Wegovy at 0.5mg: the dose that surprises most people

The biggest myth: 0.5mg means the treatment isn't working yet

The most common misconception our prescribers hear at this stage (genuinely, a question that comes up most weeks) is that feeling little effect at 0.5mg means the medicine isn't going to work. That reading is wrong, but it's understandable. The 0.5mg step is a continuation of the settling-in period, not a therapeutic plateau you should be judging results against.

Wegovy's titration schedule exists for a straightforward clinical reason: semaglutide acts on GLP-1 receptors in the gut and the brain, slowing how quickly the stomach empties and reducing appetite signals over time. Introduced too fast, these effects produce intense nausea. The slow climb from 0.25mg through 0.5mg is calibrated to minimise that. Most people will notice some appetite reduction at this stage (a feeling of fullness arriving sooner, smaller portions feeling satisfying) even if the scales haven't moved much. That is the medicine doing its early work.

The NHS medicines page for semaglutide confirms that the titration schedule is a standard feature of treatment and not a sign that anything has gone wrong. Weight loss results are measured at maintenance doses, not here. Patience, at this point, is clinically appropriate.

What 0.5mg actually feels like, and what side effects to watch for

For many people, the step from 0.25mg to 0.5mg brings a modest increase in GI symptoms: nausea, occasional loose stools, a sense of fullness that can tip into discomfort if meals are large or fatty. These effects are recognised and typically settle within a few days of the new dose. Eating smaller portions, staying well hydrated and avoiding heavy or greasy food during the first week at each new dose makes a real practical difference.

Some people sail through the 0.5mg month with minimal disruption. Others find it harder. Both are normal. What matters clinically is the pattern: mild, transient nausea is expected; severe or persistent stomach pain (especially if it radiates to the back) needs prompt medical attention, because pancreatitis, though uncommon, is a known risk with GLP-1 medicines. The MHRA issued specific guidance on this in early 2026, and it is worth reading if you have any concerns. You can also report any suspected side effects directly through the MHRA Yellow Card scheme.

Dizziness, headache, fatigue and injection-site reactions are also possible at this stage. Most pass quickly. If you are finding 0.5mg particularly hard to tolerate, talk to your prescriber, it is clinically reasonable to stay at a dose for longer than four weeks before stepping up. The pace of titration is not fixed in stone; it is a guide.

Why your prescriber, not the schedule, sets the tempo

Wegovy's dosing ladder (stepping every four weeks through to the 2.4mg maintenance dose, or the newer 7.2mg option for eligible patients) is the licensed framework, but it is your prescriber who decides whether to follow it precisely, slow it down or briefly hold a dose. That decision is based on your tolerance, any side effects you report, how your weight and health are responding, and your overall clinical picture.

This is why semaglutide is a prescription-only medicine. For a fuller picture of how the full dosing schedule fits together from the very start, the guide to Wegovy's starting dose on this site walks through the reasoning behind the initial steps. And if you are already thinking ahead to where the dose goes next, the 1mg step is where many people first notice a meaningful shift in appetite control.

At 0.5mg, the clinical task is simple: tolerate the dose well enough to move forward. That is not a failure state. It is the process working as designed.

Access, cost context and the private prescription route

Wegovy is available through NHS specialist weight management services and, for those who qualify under phased NHS criteria, through GP prescription. Many people access it privately because NHS waiting lists are long or because they do not yet meet the current NHS thresholds. For context on what private treatment costs and what a legitimate prescription-included price should cover, the cost of Wegovy in the UK page sets out an honest picture, including why headline prices that seem unusually low are worth scrutinising carefully.

At nume, every treatment cycle is reviewed by a GPhC-registered Independent Prescriber before dispatch, a real clinician reads your consultation, not software. The Wegovy overview page covers the full picture of how the medicine works, its licence and what to expect across the full treatment course, including detailed guidance for people starting Wegovy at 1.7mg or those who are ready to read about starting Wegovy at 2.4mg. If you have specific questions about your own situation before starting, our team is available seven days a week.